Description: SOA Announces First Component of Modernized Education System

Description: This session will dive into how artificial intelligence is poised to reshape the actuarial profession. Attendees will learn about the potential impacts of AI on actuarial tasks. The presentation will highlight both the opportunities and challenges that AI presents to actuaries.

Description: SOA Names Morgan State University to its University-Earned Credit Diversity Extension Program

Description: The SOA announces the evolution of the Fellowship of the SOA (FSA) pathway. The SOA is making enhancements to help meet the growing global demand for actuarial talent. These enhancements will improve the candidate learning experience and provide more flexibility and global relevancy in the curriculum while maintaining the rigor that has earned respect for the FSA designation worldwide.

Description: A compilation of reader responses is presented to a real life situation. This issue’s case study involved a candidate for an actuarial position who didn't handle salary discussions well, and whether that should impact the hiring decision.

Description: A compilation of reader responses is presented to a real life situation posed involving a management, leadership, or other business decision. This issue’s case study involved a career decision by a near FSA.

Description: The Society of Actuaries (SOA) Research Institute’s Mortality and Longevity Strategic Research Program Steering Committee established a call for essays series to gather a variety of perspectives on the application of AI to mortality and longevity. The objective of this call for essays, the second in the series, is to create a resource that focuses on the use of AI to potentially extend human longevity and the implications for modeling future survival/mortality.

Description: Short Form Professional Development Videos - AI bulletin  Recording

Description: Address issues in value-based contract accounting from an actuarial perspective. In Medicare and ACA business, what issues does risk adjustment present to value-based contract accounting? In Medicare, what issues do Part D present in value-based contract accounting and what are possible solutions? What are the issues in the use of provider stop loss in value-based contract accounting? Are there issues in the timeliness of claims in value-based contract accounting? Are we giving providers enough information for them to manage their population? How do we deal with deficit accounts? What are the pros and cons of capitation, gainshare, and full risk in value-based accounting?

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.